Metropolitan Life Insurance Company (MetLife)’s Bionano Genomics BNGO Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-27	Closed	-$18.1K	–	2466
2023 Q1	$18.1K	Sell	27 -2	-7%	-$1.78K	﹤0.01%	1929
2022 Q4	$25.7K	Hold	29	–	–	﹤0.01%	1866
2022 Q3	$32.3K	Buy	29 +9	+45%	+$11.9K	﹤0.01%	1752
2022 Q2	$16.7K	Sell	20 -12	-38%	-$12.3K	﹤0.01%	2126
2022 Q1	$49.5K	Sell	32 -97	-75%	-$131K	﹤0.01%	1595
2021 Q4	$231K	Buy	129 +18	+16%	+$48.1K	﹤0.01%	1929
2021 Q3	$366K	Sell	111 -19	-15%	-$66.5K	0.01%	1654
2021 Q2	$574K	Buy	+130	New	+$513K	0.01%	1435

Other funds holding BNGO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s BNGO Position: Q2 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Bionano Genomics (BNGO) in Q2 2023, closing a stake of 27 shares — an estimated $18.1K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in BNGO in Q2 2021 and held it in 8 quarters. The position peaked at $574K in Q2 2021. 108 funds tracked by Wall St. Rank hold BNGO as of Q2 2023.

Metropolitan Life Insurance Company (MetLife) reported no remaining Bionano Genomics position as of Q2 2023 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 27 Bionano Genomics shares in Q2 2023, an estimated $18.1K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Bionano Genomics in Q2 2021 and held it in 8 quarters.
Metropolitan Life Insurance Company (MetLife)'s Bionano Genomics position peaked at $574K in Q2 2021.
108 funds tracked by Wall St. Rank held Bionano Genomics as of Q2 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2023, filed 10 Aug 2023.